Zifanocycline is under clinical development by KBP Biosciences and currently in Phase I for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. According to GlobalData, Phase I drugs for Skin And Skin Structure Infections (SSSI) Caused By Bacteria have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zifanocycline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zifanocycline overview
Zifanocycline (KBP-7072) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSI), community-acquired bacterial pneumonia (CABP), methicillin-resistant staphylococcus aureus (MRSA) infections, penicillin-resistant streptococcus pneumoniae (PRSP), vancomycin-resistant enterococcus (VRE) infections and Acinetobacter infections. It acts by targeting 30S ribosomal subunit (30S RNA). The drug candidate is an aminomethylcycline antibiotic, administered through oral and intravenous route.
KBP Biosciences overview
KBP Biosciences is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cardiorenal and infectious diseases. The company’s lead product candidate KBP-5074, a non-steroidal mineralocorticoid receptor antagonist (MRA) is used for the treatment of uncontrolled hypertension in patients with chronic kidney diseases. KBP Biosciences investigates KBP-7072, a tetracycline formulation targeting multi drug resistant bacteria infections; KPB-7026 against eosinophilic asthma; KBP-8017, a multi kinase inhibitor to treat fibrosis caused due to radiotherapy; and KBP-7909 drug targeting gram negative bacterial infections. Its proprietary discovery platform helps in estimating pharmacokinetics/pharmacodynamics (PK/PD) and toxicology across various drug candidates. The company operates in the US. KBP BioSciences is headquartered in Shanghai, China.
For a complete picture of Zifanocycline’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
